康莱特联合吉西他滨治疗进展期胰腺癌的疗效观察

Efficacy of kanglaite combined with gemcitabine in patients with advanced pancreatic cancer

目的:观察康莱特联合吉西他滨治疗进展期胰腺癌的临床疗效、临床获益反应和不良反应。方法:40例未接受过全身化疗的进展期胰腺癌患者,至少接受2个周期的康莱特联合吉西他滨化疗方案。康莱特200ml静滴,每天1次,吉西他滨1000mg/m2,第1天和第8天,每21天为一个周期。结果:40例患者中3例临床缓解,13例部分缓解,11例稳定。总的疾病控制率为67.5%。疼痛缓解率为88.6%。骨髓抑制发生率为37.5%。无化疗相关死亡。结论:康莱特联合吉西他滨治疗进展期胰腺癌可提高疾病控制率,改善患者生活质量,减轻疼痛,减少不良反应的发生。

Objective：To evaluate the efficacy,clinical benefits and adverse reactions of kanglaite combined with gemcitabine for advanced pancreatic cancer. Methods：All 40 patients with advanced pancreatic cancer were treated with kanglaite 200ml/d, and gemcitabine 1000mg/m2 on first day and eighth day （repeated every 21 days）. All pa- tients received over two cycles of this regimen. Results：Among 40 patients disease control rate was 67.5%, including 3 CR, 13 PR and 11 SD. The rate of pain relief was 88.6%. Myelosuppression rate was 37.5%. No chemotherapy - related death occurred. Conclusion：Kanglaite in combination with gemcitabine can be used for the treatment of ad- vanced pancreatic cancer. It can improve efficacy and the quality of life, relieve pain, and reduce the adverse reactions of chemotherapy.